Learn more →
Back to Expert Scholars
clinical / clinicalskin cancer

Axel Hauschild

阿克塞尔·豪施尔德

MD, PhD

🏢University Hospital Schleswig-Holstein, Kiel(基尔石勒苏益格-荷尔斯泰因大学医院)🌐Germany

Professor of Dermatology; Head, Skin Cancer Center皮肤科教授;皮肤癌中心主任

70
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Axel Hauschild is Professor of Dermatology and Head of the Skin Cancer Center at University Hospital Schleswig-Holstein in Kiel, Germany. Internationally recognized for his prolific contributions to skin oncology trials, he has been a lead investigator in numerous pivotal studies across melanoma and non-melanoma skin cancers. In NMSC, he has led German and European cohorts in cemiplimab trials for advanced CSCC and BCC, and has championed adjuvant immunotherapy approaches for high-risk resected skin cancers.

Share:

🧪Research Fields 研究领域

Cutaneous Squamous Cell Carcinoma皮肤鳞状细胞癌
Basal Cell Carcinoma基底细胞癌
Immunotherapy for NMSC非黑色素瘤皮肤癌免疫治疗
Adjuvant Immunotherapy Skin Cancer皮肤癌辅助免疫治疗
Checkpoint Inhibitors Dermatology皮肤科检查点抑制剂

🎓Key Contributions 主要贡献

EMPOWER-CSCC European Leadership

Led German investigator sites in the EMPOWER-CSCC program evaluating cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma, contributing critical European patient data for regulatory submissions.

Adjuvant Immunotherapy for High-Risk CSCC

Pioneered investigation of adjuvant cemiplimab in resected high-risk CSCC with nodal involvement, exploring whether immune checkpoint blockade can reduce recurrence in surgically treated patients.

Representative Works 代表性著作

[1]

Adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma after curative resection: CASE trial

Journal of Clinical Oncology (2024)

Phase III trial evaluating adjuvant cemiplimab in resected stage III/IV CSCC showing significant improvement in disease-free survival.

[2]

Fixed-dose cemiplimab for advanced cutaneous squamous cell carcinoma: 4-year follow-up of the EMPOWER-CSCC-1 non-randomised, multicentre, open-label, phase 2 trial

The Lancet Oncology (2023)

Extended follow-up demonstrating sustained response durability and long-term safety of cemiplimab in advanced CSCC.

🏆Awards & Recognition 奖项与荣誉

🏆German Cancer Society's Paul Ehrlich Award
🏆European Academy of Dermatology and Venereology Research Award
🏆International Society of Dermato-Oncology Merit Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 阿克塞尔·豪施尔德 的研究动态

Follow Axel Hauschild's research updates

留下邮箱,当我们发布与 Axel Hauschild(University Hospital Schleswig-Holstein, Kiel)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment